These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35761345)

  • 1. Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials units.
    Iflaifel M; Partlett C; Bell J; Cook A; Gamble C; Julious S; Juszczak E; Linsell L; Montgomery A; Sprange K
    Trials; 2022 Jun; 23(1):535. PubMed ID: 35761345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials: a mixed methods study.
    Iflaifel M; Sprange K; Bell J; Cook A; Gamble C; Julious SA; Juszczak E; Linsell L; Montgomery A; Partlett C
    Trials; 2023 Jan; 24(1):71. PubMed ID: 36721215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recording harms in randomised controlled trials of behaviour change interventions: a qualitative study of UK clinical trials units and NIHR trial investigators.
    Papaioannou D; Sprange K; Hamer-Kiwacz S; Mooney C; Moody G; Cooper C
    Trials; 2024 Mar; 25(1):163. PubMed ID: 38438935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry.
    Phillips R; Cornelius V
    BMJ Open; 2020 Jun; 10(6):e036875. PubMed ID: 32532777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023.
    Parker RA
    Trials; 2023 Sep; 24(1):579. PubMed ID: 37691093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying research priorities for effective retention strategies in clinical trials.
    Kearney A; Daykin A; Shaw ARG; Lane AJ; Blazeby JM; Clarke M; Williamson P; Gamble C
    Trials; 2017 Aug; 18(1):406. PubMed ID: 28859674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial.
    Patsko E; Godolphin PJ; Thomas KS; Hepburn T; Mitchell EJ; Craig FE; Bath PM; Montgomery AA
    Trials; 2017 Feb; 18(1):53. PubMed ID: 28153051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative costs and activity from a sample of UK clinical trials units.
    Hind D; Reeves BC; Bathers S; Bray C; Corkhill A; Hayward C; Harper L; Napp V; Norrie J; Speed C; Tremain L; Keat N; Bradburn M
    Trials; 2017 May; 18(1):203. PubMed ID: 28464930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management.
    Kyte D; Ives J; Draper H; Calvert M
    BMJ Open; 2016 Oct; 6(10):e012281. PubMed ID: 27697875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conducting qualitative research within Clinical Trials Units: avoiding potential pitfalls.
    Cooper C; O'Cathain A; Hind D; Adamson J; Lawton J; Baird W
    Contemp Clin Trials; 2014 Jul; 38(2):338-43. PubMed ID: 24937019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of blinding on estimates of mortality in randomised clinical trials of intensive care interventions: protocol for a systematic review and meta-analysis.
    Anthon CT; Granholm A; Perner A; Laake JH; Møller MH
    BMJ Open; 2017 Jul; 7(7):e016187. PubMed ID: 28701412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DEPERROR: Risks of systematic errors in drug and non-drug randomized clinical trials assessing intervention effects in patients with unipolar depression.
    Krogh J; Hjorthøj CR; Jakobsen JC; Lindschou J; Kessing LV; Nordentoft M; Gluud C
    J Affect Disord; 2015 Jul; 179():121-7. PubMed ID: 25863907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to multiplicity in publicly funded pragmatic randomised controlled trials: a survey of clinical trials units and a rapid review of published trials.
    Pike K; Reeves BC; Rogers CA
    BMC Med Res Methodol; 2022 Feb; 22(1):39. PubMed ID: 35125091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies.
    Savović J; Jones H; Altman D; Harris R; Jűni P; Pildal J; Als-Nielsen B; Balk E; Gluud C; Gluud L; Ioannidis J; Schulz K; Beynon R; Welton N; Wood L; Moher D; Deeks J; Sterne J
    Health Technol Assess; 2012 Sep; 16(35):1-82. PubMed ID: 22989478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project.
    Wilson N; Biggs K; Bowden S; Brown J; Dimairo M; Flight L; Hall J; Hockaday A; Jaki T; Lowe R; Murphy C; Pallmann P; Pilling MA; Snowdon C; Sydes MR; Villar SS; Weir CJ; Welburn J; Yap C; Maier R; Hancock H; Wason JMS
    BMC Med; 2021 Oct; 19(1):251. PubMed ID: 34696781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
    Feys F; Bekkering GE; Singh K; Devroey D
    Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns.
    Hopkins C; Sydes M; Murray G; Woolfall K; Clarke M; Williamson P; Tudur Smith C
    J Clin Epidemiol; 2016 Feb; 70():17-25. PubMed ID: 26169841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining a risk-proportionate approach to the validation of statistical programming for clinical trials.
    Gamble C; Lewis S; Stocken D; Juszczak E; Bradburn M; Doré C; Kean S
    Clin Trials; 2024 Feb; 21(1):85-94. PubMed ID: 37957825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.